Campbell Bradley L, an insider at Amicus Therapeutics Inc (FOLD), purchased 1,207,708 shares of the biotechnology company on December 14, 2025, at a price of $9.03 per share, totaling approximately $10.91 million. Following this transaction, Bradley holds a total of 1,207,708 shares in Amicus.
Amicus Therapeutics focuses on developing therapies for metabolic diseases and is known for its marketed products, Galafold and Pombiliti + Opfolda. As of December 18, 2025, the company has a market capitalization of $3.4 billion and reported an earnings per share (EPS) of -0.05. Upcoming earnings are anticipated on April 29, 2026, with an EPS estimate of $0.03 and revenue projected at $165.6 million.
Insider purchases often signal confidence in a company's future, as executives typically have access to non-public information regarding their operations. However, it's important for investors to consider these transactions as part of a broader analysis, examining patterns across multiple insiders rather than isolated activities. Such decisions reflect the ongoing transparency required by the SEC, which mandates the reporting of insider transactions to provide insights into executive sentiment regarding their company's stock.